TBPH Theravance Biopharma, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

TBPH [NASD]

Theravance Biopharma, Inc.

Healthcare | Biotechnology | Cayman Islands

statements

Index	-	P/E	-	EPS (ttm)	-4.33	Insider Own	6.00%	Shs Outstand	59.46M	Perf Week	-7.52%
Market Cap	1.31B	Forward P/E	-	EPS next Y	-2.76	Insider Trans	0.00%	Shs Float	49.88M	Perf Month	-16.15%
Income	-246.90M	PEG	-	EPS next Q	-0.99	Inst Own	85.40%	Short Float	5.34%	Perf Quarter	-36.04%
Sales	87.90M	P/S	14.96	EPS this Y	-6.50%	Inst Trans	-6.78%	Short Ratio	5.90	Perf Half Y	-41.40%
Book/sh	-2.66	P/B	-	EPS next Y	32.20%	ROA	-48.50%	Target Price	-	Perf Year	-10.33%
Cash/sh	6.65	P/C	2.70	EPS next 5Y	11.40%	ROE	134.80%	52W Range	15.72 - 31.54	Perf YTD	-30.63%
Dividend	-	P/FCF	-	EPS past 5Y	10.60%	ROI	-106.70%	52W High	-43.06%	Beta	1.53
Dividend %	-	Quick Ratio	-	Sales past 5Y	44.40%	Gross Margin	-	52W Low	14.25%	ATR	0.94
Employees	316	Current Ratio	5.40	Sales Q/Q	275.50%	Oper. Margin	-	RSI (14)	28.15	Volatility	5.23% 4.22%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-5.70%	Profit Margin	-	Rel Volume	1.65	Prev Close	20.84
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 06 AMC	Payout	-	Avg Volume	451.30K	Price	17.96
Recom	2.30	SMA20	-14.70%	SMA50	-19.77%	SMA200	-23.43%	Volume	744,005	Change	-13.82%

Jul-07-20

Initiated

JP Morgan

Overweight

$29

Jun-15-20

Initiated

Morgan Stanley

Equal-Weight

$30

May-13-20

Initiated

Cowen

Outperform

$42

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$25 → $30

Nov-06-19

Upgrade

Robert W. Baird

Underperform → Neutral

$22 → $18

Oct-29-19

Initiated

H.C. Wainwright

Buy

$25

Mar-29-18

Resumed

Piper Jaffray

Overweight

$45

Aug-17-17

Initiated

Evercore ISI

Outperform

$45

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$55

May-11-17

Reiterated

Needham

Buy

$40 → $45

Dec-21-16

Initiated

Needham

Buy

$40

Nov-03-16

Initiated

Piper Jaffray

Overweight

Oct-12-16

Downgrade

Robert W. Baird

Neutral → Underperform

$19 → $24

Aug-03-16

Downgrade

BofA/Merrill

Neutral → Underperform

Jun-20-16

Reiterated

Leerink Partners

Outperform

$26 → $29

Jun-20-16

Initiated

Guggenheim

Buy

$30

May-12-16

Initiated

Leerink Partners

Outperform

$26

May-05-16

Downgrade

BofA/Merrill

Buy → Neutral

Feb-03-15

Upgrade

Robert W. Baird

Underperform → Neutral

$13 → $17

Aug-14-14

Downgrade

Robert W. Baird

Neutral → Underperform

$21

Aug-07-20 01:27PM	Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2 Zacks -13.82%
Aug-06-20 06:35PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:34PM	Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire
Jul-30-20 12:34PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-27-20 06:00AM	Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020 PR Newswire
Jul-22-20 12:32PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-02-20 06:00AM	Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors PR Newswire
Jun-29-20 03:50PM	Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Jun-26-20 12:04PM	Theravance Doses First Patient in Phase II Coronavirus Study Zacks
Jun-25-20 08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga
06:00AM	Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Jun-17-20 09:38PM	GSK Finance (No.3) plc -- Moody's assigns A2 rating to GSK Finance (No.3) plc's proposed exchangeable notes Moody's -9.05%
Jun-15-20 09:57AM	Benzinga's Top Upgrades, Downgrades For June 15, 2020 Benzinga -6.61%
Jun-05-20 11:31AM	Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-02-20 09:02PM	Edited Transcript of TBPH earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 02:31PM	Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 01:57PM	Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-06-20 07:35PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates Zacks
Apr-29-20 12:33PM	Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-28-20 12:33PM	Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know Zacks
10:35AM	Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay Simply Wall St.
06:00AM	Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020 PR Newswire
Apr-23-20 06:00AM	Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Apr-20-20 06:00AM	Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis PR Newswire
Apr-14-20 04:41PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com
Apr-09-20 07:00AM	Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury PR Newswire +5.11%
Mar-25-20 11:30AM	Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue? Zacks -5.40%
Mar-23-20 06:32PM	Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 Investor's Business Daily
Mar-20-20 08:02PM	Seth Klarman Sees Bargains as the Market Heads Further Into Chaos GuruFocus.com
Mar-02-20 07:00AM	Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes PR Newswire
Feb-27-20 02:49PM	Analysts Have Lowered Expectations For Theravance Biopharma, Inc. After Its Latest Results Simply Wall St.
Feb-25-20 02:53PM	Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates Zacks
02:06AM	Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-24-20 06:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates Zacks -8.77%
Feb-18-20 07:00AM	Theravance Biopharma Announces Presentations at Upcoming Investor Conferences PR Newswire
Feb-17-20 12:30PM	Analysts Estimate Theravance Biopharma (TBPH) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-11-20 11:05PM	Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares PR Newswire -8.80%
02:21PM	How Does Investing In Theravance Biopharma, Inc. (NASDAQ:TBPH) Impact The Volatility Of Your Portfolio? Simply Wall St.
Feb-05-20 10:27AM	Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Jan-19-20 09:13AM	3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
Jan-07-20 04:48PM	Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-24-19 09:16AM	AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod Zacks
Dec-23-19 08:15AM	Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program PR Newswire
Dec-22-19 11:10AM	Hedge Funds Have Never Been Less Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Dec-10-19 12:22PM	Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-05-19 11:31AM	Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 07:50AM	Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Nov-26-19 04:15PM	Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Nov-09-19 10:43AM	Edited Transcript of TBPH earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-19 04:30PM	Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference PR Newswire
11:19AM	Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates Zacks
Nov-05-19 06:35PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
11:24AM	What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings? Zacks
Oct-29-19 04:15PM	Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5 PR Newswire
10:32AM	Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-28-19 05:49PM	Here is What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey
Oct-21-19 04:00PM	Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting PR Newswire
Oct-07-19 10:25AM	Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Oct-02-19 01:34PM	Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares? Simply Wall St.
07:05AM	AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA Zacks
Sep-25-19 04:05PM	Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-23-19 01:16PM	Seth Klarman Further Increases Translate Bio Stake GuruFocus.com
Sep-10-19 01:58PM	Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +8.88%
11:46AM	Theravance Announces Positive Early Data on JAK Inhibitor Zacks
Sep-09-19 07:05AM	Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Aug-28-19 04:30PM	Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Aug-12-19 10:47AM	Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-11-19 08:32AM	How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility Simply Wall St.
Aug-09-19 08:24AM	Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM	Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-07-19 11:20AM	Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 09:18AM	Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2 Zacks
Aug-02-19 05:44PM	Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-01-19 03:37PM	Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates Zacks
Jul-31-19 03:27PM	Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript Motley Fool
08:35AM	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:05AM	Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Jul-22-19 08:05AM	Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress PR Newswire
Jul-18-19 02:33PM	New antibiotics desperately needed for rising tide of drug-resistant superbugs American City Business Journals
Jun-27-19 11:27AM	How Much Did Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pocket Last Year? Simply Wall St.
Jun-25-19 07:42AM	Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium MarketWatch
Jun-20-19 09:18AM	AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod Zacks
Jun-18-19 09:00AM	Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress PR Newswire
Jun-17-19 03:31PM	Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years Simply Wall St.
Jun-15-19 12:38PM	The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 08:05AM	Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories PR Newswire
Jun-06-19 09:31AM	Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-04-19 08:30AM	Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer PR Newswire
May-22-19 09:50AM	Lilly's Crohn's Disease Candidate Meets Phase II Study Goals Zacks
May-21-19 07:01AM	Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019 PR Newswire
May-20-19 10:15AM	Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference PR Newswire
May-14-19 11:39PM	Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript Motley Fool
02:21PM	Edited Transcript of TBPH earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
08:30AM	Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019 PR Newswire
May-08-19 11:44AM	Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates Zacks -9.49%
May-07-19 07:15PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:12PM	Theravance Bio: 1Q Earnings Snapshot Associated Press
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
May-02-19 01:20PM	Heres What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey +6.52%

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SABESAN VIJAY	SVP, Technical Operations	Dec 12	Sale	21.03	1,027	21,598	145,253	Dec 16 06:09 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience